Scorpius Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Scorpius Holdings zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Heat Biologics signs a licensing agreement; Appoints new CFO

Jan 06

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

Dec 16

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Nov 20

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 02

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Scorpius Holdings jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

OTCPK:SCPX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2024	10	-32	-22	-22	N/A
12/31/2023	7	-40	-34	-32	N/A
9/30/2023	2	-53	-41	-38	N/A
6/30/2023	2	-52	-44	-26	N/A
3/31/2023	1	-45	-30	-9	N/A
12/31/2022	0	-41	-26	-6	N/A
9/30/2022	1	-38	-29	-9	N/A
6/30/2022	1	-36	-30	-29	N/A
3/31/2022	2	-36	-46	-43	N/A
12/31/2021	2	-35	-40	-38	N/A
9/30/2021	2	-28	-35	-33	N/A
6/30/2021	2	-29	-27	-23	N/A
3/31/2021	3	-27	-22	-21	N/A
12/31/2020	3	-26	-22	-22	N/A
9/30/2020	4	-23	-16	-16	N/A
6/30/2020	4	-20	-15	-15	N/A
3/31/2020	3	-21	-15	-14	N/A
12/31/2019	3	-20	-13	-13	N/A
9/30/2019	3	-22	-19	-19	N/A
6/30/2019	5	-19	-18	-18	N/A
3/31/2019	6	-18	-22	-22	N/A
12/31/2018	6	-16	-22	-22	N/A
9/30/2018	4	-14	-13	-13	N/A
6/30/2018	3	-13	-13	-13	N/A
3/31/2018	2	-12	-8	-7	N/A
12/31/2017	2	-12	N/A	-6	N/A
9/30/2017	1	-12	N/A	-12	N/A
6/30/2017	1	-11	N/A	-10	N/A
3/31/2017	0	-11	N/A	-12	N/A
12/31/2016	0	-13	N/A	-14	N/A
9/30/2016	0	-16	N/A	-16	N/A
6/30/2016	N/A	-19	N/A	-18	N/A
3/31/2016	N/A	-21	N/A	-18	N/A
12/31/2015	N/A	-20	N/A	-17	N/A
9/30/2015	N/A	-17	N/A	-15	N/A
6/30/2015	N/A	-15	N/A	-14	N/A
3/31/2015	N/A	-13	N/A	-12	N/A
12/31/2014	N/A	-12	N/A	-10	N/A
9/30/2014	N/A	-10	N/A	-9	N/A
6/30/2014	N/A	-10	N/A	-9	N/A
3/31/2014	N/A	-8	N/A	-8	N/A
12/31/2013	N/A	-9	N/A	-6	N/A
9/30/2013	N/A	-8	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von SCPX über der Sparquote liegt (2.4%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von SCPX schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SCPX in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von SCPX schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von SCPX schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von SCPX in 3 Jahren voraussichtlich hoch sein wird

Scorpius Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Price target decreased to US$21.83

Price target decreased to US$23.83

Consensus forecasts updated

Consensus forecasts updated

Recent updates

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Heat Biologics signs a licensing agreement; Appoints new CFO

New 90-day low: US$5.28

Analysts update estimates

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

New 90-day low: US$1.01

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Earnings released

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite